Monoclonal antibodies and thromboembolism.
For many years intensive efforts to reliably image thrombi by radionuclide techniques have been unrewarding. Recently, however, monoclonal antibodies to platelet cell-surface antigens and to fibrin polymer have emerged as potent thrombus imaging agents in experimental animals. In Britain antiplatelet antibody has been successful in clinical trials, as has antifibrin in the United States. It is to be hoped that radiolabeled antibody technology will evolve to the point where it can detect thrombi anywhere, including the lungs and brain. The relative efficacy of radionuclide thrombus detection and Doppler ultrasonography is currently undefined.